Methyl 2-acetamido-3-[azanylidyne(oxo)-lambda6-sulfanyl]-3-methylbutanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Methyl 2-acetamido-3-[azanylidyne(oxo)-lambda6-sulfanyl]-3-methylbutanoate
• 英文别名: methyl 2-acetamido-3-[azanylidyne(oxo)-λ6-sulfanyl]-3-methylbutanoate
• 化学式: C₈H₁₄N₂O₄S
• 分子量: 234.28
• InChiKey: KKKCXIIPBWTWBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.33
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  97.3
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] NSAIDs DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS D'ANTI-INFLAMMATOIRES NON STÉROÏDIENS (AINS) ET LEURS UTILISATIONS
  申请人：UNIV CITY NEW YORK RES FOUND

  公开号：WO2014124208A1

  公开（公告）日：2014-08-14

  The present invention discloses novel compounds derived from NSAIDs and pharmaceutically acceptable salts thereof. Other aspects of the invention relate to use of the NSAID derivatives in treating inflammatory diseases and pharmaceutical compositions thereof. Non-steroidal anti-inflammatory drugs (NSAIDs) are prototypical agents for treatment of inflammatory conditions. NSAIDs may also have utility as therapeutic agents against many forms of cancers. However, long-term use of NSAIDs may lead to serious side effects affecting the gastrointestinal and renal systems.

  本发明公开了源自非甾体抗炎药（NSAIDs）的新化合物及其药用可接受的盐。发明的其他方面涉及使用这些非甾体抗炎药衍生物来治疗炎症性疾病以及相应的药物组合物。非甾体抗炎药（NSAIDs）是治疗炎症状况的典型药物。NSAIDs还可能作为许多形式癌症的治疗剂而具有实用价值。然而，长期使用NSAIDs可能会导致影响胃肠和肾脏系统的严重副作用。
• NO- AND H2S- RELEASING COMPOUNDS
  申请人：Kashfi Khosrow

  公开号：US20140221316A1

  公开（公告）日：2014-08-07

  This disclosure relates to novel compounds containing an H 2 S releasing moiety and a nitric oxide (NO) releasing moiety covalently linked with a core (e.g., a salicylic acid moiety) and the use of such compounds in treating inflammatory diseases, including cancers. Therapeutic potency of these compounds is significantly higher than NSAIDs containing a H 2 S-releasing moiety alone (HS-NSAIDs) and NSAID containing a NO-releasing moiety alone (NO-NSAIDs). The compounds, in addition, exhibit reduced side effect, e.g., reduced stomach ulcers, upon administration.

  本公开涉及新型化合物，其包含一个释放H2S的基团和一个共价连接于核心（例如水杨酸基团）的释放一氧化氮（NO）的基团，并且这些化合物的用途是治疗炎症性疾病，包括癌症。这些化合物的治疗效力明显高于仅含有释放H2S的基团（HS-NSAIDs）和仅含有释放NO的基团（NO-NSAIDs）的非甾体类抗炎药（NSAIDs）。此外，这些化合物在治疗中表现出较少的副作用，例如减少胃溃疡。
• NSAIDs DERIVATIVES AND USES THEREOF
  申请人：THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK

  公开号：US20150376162A1

  公开（公告）日：2015-12-31

  The present invention discloses novel compounds derived from NSAIDs and pharmaceutically acceptable salts thereof. Other aspects of the invention relate to use of the NSAID derivatives in treating inflammatory diseases and pharmaceutical compositions thereof.

  本发明揭示了从非甾体抗炎药（NSAIDs）衍生出的新化合物及其药学上可接受的盐。本发明的其他方面涉及使用NSAID衍生物治疗炎症性疾病以及其制药组合物。
• Method of Priming Plants Against Abiotic Stress Factors
  申请人：Research Foundation of the City University of New York

  公开号：US20170174651A1

  公开（公告）日：2017-06-22

  A method of reducing cellular damage to a plant by treating the plant with a compound containing an NO-releasing moiety and an H 2 S-releasing moiety covalently bonded to an aspirin derived core or a NOSH compound is claimed. The compounds may also be used in a method of priming a plant against abiotic stress factors and a method of promoting plant growth.